CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Balance at beginning of period at Dec. 31, 2022	$ 1	$ 880,832	$ (897)	$ (682,315)	$ 197,621
Balance at beginning of period (in shares) at Dec. 31, 2022	66,688,647
Increase (Decrease) in Stockholders' Equity
Issuance of common stock in connection with vesting of restricted stock units (in shares)	517,378
Unrealized gain (loss) on marketable securities			543		543
Stock-based compensation expense		6,806			6,806
Net loss				(28,160)	(28,160)
Balance at end of period at Mar. 31, 2023	$ 1	887,638	(354)	(710,475)	176,810
Balance at end of period (in shares) at Mar. 31, 2023	67,206,025
Balance at beginning of period at Dec. 31, 2022	$ 1	880,832	(897)	(682,315)	197,621
Balance at beginning of period (in shares) at Dec. 31, 2022	66,688,647
Increase (Decrease) in Stockholders' Equity
Net loss					(57,729)
Balance at end of period at Jun. 30, 2023	$ 1	920,904	(1,111)	(740,044)	179,750
Balance at end of period (in shares) at Jun. 30, 2023	70,769,702
Balance at beginning of period at Mar. 31, 2023	$ 1	887,638	(354)	(710,475)	176,810
Balance at beginning of period (in shares) at Mar. 31, 2023	67,206,025
Increase (Decrease) in Stockholders' Equity
Issuance of common stock in connection with vesting of restricted stock units		30			30
Issuance of common stock in connection with vesting of restricted stock units (in shares)	163,677
Issuance of common stock under at-the-market sales agreement, net of offering costs of $826		26,714			26,714
Issuance of common stock under at-the-market sales agreement, net of offering costs of $826 (In shares)	3,400,000
Unrealized gain (loss) on marketable securities			(757)		(757)
Stock-based compensation expense		6,522			6,522
Net loss				(29,569)	(29,569)
Balance at end of period at Jun. 30, 2023	$ 1	920,904	(1,111)	(740,044)	179,750
Balance at end of period (in shares) at Jun. 30, 2023	70,769,702
Balance at beginning of period at Dec. 31, 2023	$ 1	928,080	(106)	(770,796)	$ 157,179
Balance at beginning of period (in shares) at Dec. 31, 2023	70,894,889				70,894,889
Increase (Decrease) in Stockholders' Equity
Issuance of common stock in connection with vesting of restricted stock units		(55)			$ (55)
Issuance of common stock in connection with vesting of restricted stock units (in shares)	353,128
Unrealized gain (loss) on marketable securities			(258)		(258)
Stock-based compensation expense		2,089			2,089
Net loss				(16,941)	(16,941)
Balance at end of period at Mar. 31, 2024	$ 1	930,114	(364)	(787,737)	142,014
Balance at end of period (in shares) at Mar. 31, 2024	71,248,017
Balance at beginning of period at Dec. 31, 2023	$ 1	928,080	(106)	(770,796)	$ 157,179
Balance at beginning of period (in shares) at Dec. 31, 2023	70,894,889				70,894,889
Increase (Decrease) in Stockholders' Equity
Net loss					$ (27,927)
Balance at end of period at Jun. 30, 2024	$ 1	933,007	(463)	(798,723)	$ 133,822
Balance at end of period (in shares) at Jun. 30, 2024	71,332,825				71,332,825
Balance at beginning of period at Mar. 31, 2024	$ 1	930,114	(364)	(787,737)	$ 142,014
Balance at beginning of period (in shares) at Mar. 31, 2024	71,248,017
Increase (Decrease) in Stockholders' Equity
Issuance of common stock in connection with vesting of restricted stock units		(10)			(10)
Issuance of common stock in connection with vesting of restricted stock units (in shares)	84,808
Unrealized gain (loss) on marketable securities			(99)		(99)
Stock-based compensation expense		2,903			2,903
Net loss				(10,986)	(10,986)
Balance at end of period at Jun. 30, 2024	$ 1	$ 933,007	$ (463)	$ (798,723)	$ 133,822
Balance at end of period (in shares) at Jun. 30, 2024	71,332,825				71,332,825